ROSETTA HCC-206: An Open-Label, Multi-Center, Randomized Phase 1/2 Study of Pumitamig Alone or in Combination with Ipilimumab in Participants with First-Line Advanced or Unresectable Hepatocelluar Carcinoma (HCC)